PortfoliosLab logoPortfoliosLab logo
APRE vs. EPR
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

APRE vs. EPR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Aprea Therapeutics, Inc. (APRE) and EPR Properties (EPR). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, APRE achieves a -2.93% return, which is significantly lower than EPR's 21.91% return.


APRE

1D
4.33%
1M
-12.84%
YTD
-2.93%
6M
-13.00%
1Y
-48.25%
3Y*
-35.92%
5Y*
-61.59%
10Y*

EPR

1D
1.96%
1M
1.50%
YTD
21.91%
6M
23.79%
1Y
6.95%
3Y*
18.89%
5Y*
9.67%
10Y*
3.41%
*Multi-year figures are annualized to reflect compound growth (CAGR)

APRE vs. EPR - Yearly Performance Comparison


2026 (YTD)2025202420232022202120202019
APRE
Aprea Therapeutics, Inc.
-2.93%-74.07%-30.00%-29.00%-88.47%-41.67%-89.28%196.83%
EPR
EPR Properties
21.91%20.52%-1.25%38.83%-14.61%50.60%-52.09%-6.16%

Correlation

The correlation between APRE and EPR is 0.07, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.07

Correlation (3Y)
Calculated over the trailing 3-year period

0.09

Correlation (5Y)
Calculated over the trailing 5-year period

0.12

Correlation (All Time)
Calculated using the full available price history since Oct 3, 2019

0.10

Fundamentals

Market Cap

APRE:

$12.16M

EPR:

$4.53B

EPS

APRE:

-$1.37

EPR:

$3.55

PS Ratio

APRE:

61.04

EPR:

6.47

PB Ratio

APRE:

0.30

EPR:

1.96

Total Revenue (TTM)

APRE:

$118.11K

EPR:

$700.22M

Gross Profit (TTM)

APRE:

-$1.79M

EPR:

$568.77M

EBITDA (TTM)

APRE:

-$12.56M

EPR:

$582.57M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

APRE vs. EPR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

APRE
APRE Risk / Return Rank: 2020
Overall Rank
APRE Sharpe Ratio Rank: 1919
Sharpe Ratio Rank
APRE Sortino Ratio Rank: 2121
Sortino Ratio Rank
APRE Omega Ratio Rank: 2222
Omega Ratio Rank
APRE Calmar Ratio Rank: 1717
Calmar Ratio Rank
APRE Martin Ratio Rank: 2121
Martin Ratio Rank

EPR
EPR Risk / Return Rank: 4949
Overall Rank
EPR Sharpe Ratio Rank: 5353
Sharpe Ratio Rank
EPR Sortino Ratio Rank: 4545
Sortino Ratio Rank
EPR Omega Ratio Rank: 4545
Omega Ratio Rank
EPR Calmar Ratio Rank: 5151
Calmar Ratio Rank
EPR Martin Ratio Rank: 5050
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

APRE vs. EPR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Aprea Therapeutics, Inc. (APRE) and EPR Properties (EPR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


APREEPRDifference
Sharpe ratioReturn per unit of total volatility

-0.84

Sortino ratioReturn per unit of downside risk

-1.05

Omega ratioGain probability vs. loss probability

0.95

1.07

-0.13

Calmar ratioReturn relative to maximum drawdown

-0.68

0.36

-1.03

Martin ratioReturn relative to average drawdown

-1.00

0.71

-1.71

APRE vs. EPR - Sharpe Ratio Comparison

The current APRE Sharpe Ratio is -0.54, which is lower than the EPR Sharpe Ratio of 0.31. The chart below compares the historical Sharpe Ratios of APRE and EPR, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

APRE vs. EPR - Drawdown Comparison

The maximum APRE drawdown since its inception was -99.94%, which is greater than EPR's maximum drawdown of -82.02%. Use the drawdown chart below to compare losses from any high point for APRE and EPR.


Loading charts...

Drawdown Indicators


APREEPRDifference

Max Drawdown

Largest peak-to-trough decline

-99.94%

-82.02%

-17.92%

Max Drawdown (1Y)

Largest decline over 1 year

-71.63%

-19.51%

-52.12%

Max Drawdown (3Y)

Largest decline over 3 years

-93.03%

-19.51%

-73.52%

Max Drawdown (5Y)

Largest decline over 5 years

-99.48%

-35.63%

-63.85%

Max Drawdown (10Y)

Largest decline over 10 years

-82.02%

Current Drawdown

Current decline from peak

-99.92%

-1.12%

-98.80%

Average Drawdown

Average peak-to-trough decline

-85.45%

-16.57%

-68.88%

Ulcer Index

Depth and duration of drawdowns from previous peaks

48.16%

9.82%

+38.34%

Volatility

APRE vs. EPR - Volatility Comparison

Aprea Therapeutics, Inc. (APRE) has a higher volatility of 24.65% compared to EPR Properties (EPR) at 6.40%. This indicates that APRE's price experiences larger fluctuations and is considered to be riskier than EPR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


APREEPRDifference

Volatility (1M)

Calculated over the trailing 1-month period

24.65%

6.40%

+18.25%

Volatility (6M)

Calculated over the trailing 6-month period

75.16%

16.94%

+58.22%

Volatility (1Y)

Calculated over the trailing 1-year period

90.25%

22.68%

+67.57%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

85.85%

26.14%

+59.71%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

90.82%

42.48%

+48.34%

Dividends

APRE vs. EPR - Dividend Comparison

APRE has not paid dividends to shareholders, while EPR's dividend yield for the trailing twelve months is around 6.06%.


PositionTTM20252024202320222021202020192018201720162015
APRE
Aprea Therapeutics, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
EPR
EPR Properties
6.06%7.05%7.68%6.81%8.62%3.16%4.66%6.37%5.62%6.23%5.35%6.21%

Financials

APRE vs. EPR - Financials Comparison

This section allows you to compare key financial metrics between Aprea Therapeutics, Inc. and EPR Properties. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00M200.00M202220232024202520260
181.25M
(APRE) Total Revenue
(EPR) Total Revenue
Values in USD except per share items

Frequently Asked Questions


APRE and EPR have a correlation of 0.07, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

APRE has higher volatility (24.65%) compared to EPR (6.40%). In terms of maximum drawdown, APRE dropped -99.94% vs EPR's -82.02%.

EPR currently has the higher Sharpe Ratio (0.31 vs -0.54), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for APRE and EPR

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer